Drugs / activated autologous NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01875601 | Jun 2013 → Sep 2015 | brain cancer, childhood malignant neoplasm, neuroblastoma, sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | activated autologous NK cells | “Cohort A receives escalating doses of activated autologous NK cells to identify feasibility of generating cells and tolerability” NCT01875601 ↗ |
| Action | Deplete | “Activated NK cells potently kill autologous pediatric solid tumors” NCT01875601 ↗ |
| Modality | Cell therapy | “generate large numbers of activated NK cells for adoptive cell therapy” NCT01875601 ↗ |